RECRUITING

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

Description

The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.

Conditions

Idiopathic Pulmonary Fibrosis
Talk to us

Related Conditions:

Idiopathic Pulmonary Fibrosis

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.

A Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

Condition
Idiopathic Pulmonary Fibrosis
Intervention / Treatment

-

Contacts and Locations

Miami

Y & L Advance Health Care, Inc. d/b/a Elite Clinical Research, Miami, Florida, United States, 33144

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥ 40 years of age
  • * Diagnosis of IPF supported by centrally read chest high-resolution computed tomography
  • * Definite or probable usual interstitial pneumonia (UIP) pattern on chest high-resolution computed tomography (HRCT) performed within 12 months of screening, confirmed by central review (if an evaluable HRCT \< 12 months is not available, the baseline HRCT will be used to determine eligibility).
  • * FVC ≥ 45% of predicted.
  • * Diffusing capacity of the lung for carbon monoxide (DLCO) ≥ 25% predicted.
  • * Forced expiratory volume in 1 second (FEV1)/FVC ≥ 0.7
  • * Either stable dose with antifibrotics (either nintedanib or pirfenidone) for at least 8 weeks prior to screening or not treated with antifibrotics for at least 8 weeks prior to screening.
  • * In the opinion of the Investigator, other clinically significant lung disease (e.g. asthma, emphysema, chronic obstructive pulmonary disease, cavitary or pleural diseases) at screening.
  • * Interstitial lung disease (ILD) other than IPF (including, but not limited to, connective tissue diseases, vasculitis).
  • * Acute IPF exacerbation within 16 weeks prior to screening and/or during the screening period (investigator-determined).
  • * Lower respiratory tract infection requiring antibiotics within 4 weeks prior to screening and/or during the screening period.
  • * Evidence of impaired kidney function, unstable cardiovascular disease, moderate or severe hepatic impairment or any significant disease or condition other than IPF which may interfere with trial procedures or interpretation of trial results, or cause concern regarding the patient's ability to participate in the trial or any medical condition which could lead to a life expectancy \< 12months

Ages Eligible for Study

40 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Calluna Pharma AS,

Study Record Dates

2027-11